AbbVie Extends Reach Of Regenxbio’s Wet AMD Program

Regenxbio Inc. will have sufficient resources to extend the global reach of RGX-314, its gene therapy for wet age-related macular degeneration (AMD) and diabetic retinopathy (DR), through a partnership with AbbVie Inc. worth potentially as much as $1.75bn. The company also stands to benefit from AbbVie’s expertise in eye diseases, without which the gene therapy maker may have found itself left to compete alone against other large drug makers in the space.

Rockville, MD-based Regenxbio and Chicago-based AbbVie said on 13 September that they entered into a development and commercialization deal, whereby AbbVie is paying $370m up front, plus up to $1.38bn in milestone fees and a 50-50 split of profits from RGX-314